Denmark’s MinervaX has raised €47.4 million (around $56 million) in a Series B funding round to take its novel group B streptococcus (GBS) vaccine into mid-stage clinical trials. When and if the ...
🛍️ La Mesa Macy’s closing 🍸 Padres’ new cocktail lounge 🚌 San Diego jobs report 🐶 Humane Society animal hospital 🌼 Superbloom on the way?
A guide to San Diego area community events for Hanukkah–the Festival of Lights By Linda Mcintosh December 14, 2025 at 7:17 a.m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback